Valuation: Jade Biosciences, Inc.

Market Cap 127.68Cr 111.62Cr 102.58Cr 96Cr 181.36Cr 12TCr 184.11Cr 1.23TCr 478.73Cr 5.98TCr 479.27Cr 468.98Cr 21TCr P/E 2026 *
-8.27x
P/E 2027 * -8.35x
Enterprise Value 102.33Cr 89Cr 82Cr 77Cr 145.35Cr 9.74TCr 147.55Cr 986.96Cr 383.68Cr 4.79TCr 384.11Cr 375.86Cr 17TCr EV / Sales 2026 *
-
EV / Sales 2027 * -
Free-Float
99.15%
Yield 2026 *
-
Yield 2027 * -

Last Transcript: Jade Biosciences, Inc.

1 day-1.38%
1 week-2.23%
Current month-3.20%
1 month+21.25%
3 months+38.86%
6 months+51.91%
Current year+39.40%
1 week 20.2
Extreme 20.2
23.12
1 month 14.28
Extreme 14.28
23.49
Current year 12.45
Extreme 12.45
28
1 year 6.67
Extreme 6.67
28
3 years 6.56
Extreme 6.565
28
5 years 6.56
Extreme 6.565
28
10 years 6.56
Extreme 6.565
28
Manager TitleAgeSince
Chief Executive Officer 50 28/04/2025
Director of Finance/CFO 38 14/07/2025
Chief Tech/Sci/R&D Officer 53 22/04/2026
Director TitleAgeSince
Director/Board Member 50 28/04/2025
Director/Board Member 42 28/04/2025
Chairman 57 28/04/2025
Date Insider Type Main position Quantity % Market Cap.
25/06Free

Director

47,675 0.0966%
09/06
Fairmount Funds Management LLC
FreeCompany 34,843 0.0706%
09/06Free

Director

34,843 0.0706%
Change 5-day change 1-year change 3-year change Capi.($)
-1.38%-2.23%+93.09% - 127.68Cr
+1.70%+7.41%+2.50%+8.22% 4.99TCr
+0.92%+3.93%+399.71%+605.33% 4.02TCr
+1.89%+8.32%+26.06%-6.35% 3.46TCr
+2.38%+6.35%+21.25%+64.58% 3.31TCr
+3.96%+10.67%+8.30%+40.44% 2.75TCr
+2.51%+5.27% - - 1.7TCr
+2.58%+5.79%+73.44%+133.27% 1.59TCr
+0.32%+0.58%+14.00%+19.59% 1.39TCr
+3.30%+0.76%+90.23%+99.12% 1.35TCr
Average +1.82%+5.10%+80.95%+120.52% 2.47TCr
Weighted average by Cap. +2.05%+6.49%+90.22%+137.91%

Financials

2026 *2027 *
Net sales - -
Net income -17Cr -15Cr -14Cr -13Cr -25Cr -1.65TCr -25Cr -167.05Cr -65Cr -810.64Cr -65Cr -64Cr -2.79TCr -19Cr -17Cr -15Cr -14Cr -27Cr -1.82TCr -28Cr -184.39Cr -72Cr -894.76Cr -72Cr -70Cr -3.08TCr
Net Debt -25Cr -22Cr -20Cr -19Cr -36Cr -2.41TCr -37Cr -244.52Cr -95Cr -1.19TCr -95Cr -93Cr -4.09TCr -30Cr -26Cr -24Cr -22Cr -43Cr -2.86TCr -43Cr -289.61Cr -112.58Cr -1.41TCr -112.71Cr -110.29Cr -4.84TCr
Logo Jade Biosciences, Inc.
Jade Biosciences, Inc. is a biotechnology company, which is focused on developing therapies for autoimmune diseases. The Company’s lead asset, JADE-001, is an investigational anti-A PRoliferation-Inducing Ligand (APRIL) monoclonal antibody for the treatment of Immunoglobulin A (IgA) nephropathy (IgAN), an autoimmune condition in which the kidney is damaged by pathogenic IgA containing immune complexes, leading to proteinuria and kidney function decline, and potentially progressing to end-stage kidney disease requiring dialysis or transplantation. Designed to block the APRIL protein, JADE-001 targets an underlying cause of IgAN, offering the potential to reduce pathogenic IgA levels, decrease proteinuria, and preserve kidney function over the long term. The Company’s pipeline also includes two undisclosed antibody discovery programs: JADE-002 and JADE-003, which are in preclinical development.
Employees
55
Date Price Change Volume
02/26/02 $21.51 -1.38% 12,04,531
01/26/01 $21.81 -1.85% 8,61,567
30/26/30 $22.22 +0.50% 8,93,408
29/26/29 $22.11 +0.50% 11,22,561
26/26/26 $22.00 +0.87% 26,64,341
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BBB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
10
Last Close Price
21.51USD
Average target price
48.50USD
Spread / Average Target
+125.48%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. JBIO Stock